US EditionIndonesian Military's New Pharma Role Sparks Fears of Expanded Powers
INDONESIA, JUL 23 – Indonesia's military will distribute medicines at 50% below retail price through 80,000 state-backed cooperatives to boost economic activity and reduce middlemen, officials said.
- Indonesia's military will manufacture medicines for public use under a new agreement, as announced by Defence Minister Sjafrie Sjamsoeddin.
- Mass production of the medicines is set to begin in October, and they will be sold at 50% below retail price through 80,000 cooperatives.
- Rights groups claim the agreement is unlawful for allowing military officials to hold civilian business roles, contravening military law.
- Usman Hamid from Amnesty International Indonesia expressed concerns about a shift towards authoritarianism in the government.
11 Articles
11 Articles
Malay Mail
AlKhaleej TodayIndonesia expands military role into medicine production, sparking authoritarianism fears
JAKARTA, July 24 — Indonesia’s military will begin manufacturing medicines for public distribution under a new agreement, officials said yesterday, in the latest expansion of the armed forces’ role in civilian affairs since President Prabowo Subianto took office.The president, a former defence minister and special forces commander, has expanded the powerful military’s role in civic affairs since taking office last year — including running much o…
Channel News Asia
Indonesian military's new pharma role sparks fears of expanded powers
President Prabowo Subianto - a former defence minister and special forces commander - has expanded the powerful military's role in civic affairs since taking office last year.
Indonesian Military’s New Pharma Role Raises Concerns Over Expanding Authority
In March, the Indonesian President's coalition-led parliament passed a military law revision allowing more civilian roles for soldiers, prompting protests from student and activist groups. The post Indonesian Military’s New Pharma Role Raises Concerns Over Expanding Authority appeared first on StratNews Global.
Coverage Details
Bias Distribution
- 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
